Maryland State Retirement & Pension System Sells 372 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Maryland State Retirement & Pension System decreased its position in Omnicell, Inc. (NASDAQ:OMCL) by 2.3% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,012 shares of the company’s stock after selling 372 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Omnicell were worth $433,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of OMCL. Panagora Asset Management Inc. purchased a new position in shares of Omnicell in the fourth quarter worth approximately $1,319,000. Vanguard Group Inc. grew its position in shares of Omnicell by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after acquiring an additional 80,312 shares during the period. Mutual of America Capital Management LLC increased its stake in shares of Omnicell by 197.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock worth $3,642,000 after purchasing an additional 82,774 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Omnicell by 61.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after purchasing an additional 228,093 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Omnicell during the first quarter valued at $684,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Stock Down 1.1 %

OMCL opened at $44.00 on Wednesday. The company has a market capitalization of $2.02 billion, a PE ratio of -95.65, a price-to-earnings-growth ratio of 49.29 and a beta of 0.80. The firm has a 50-day simple moving average of $34.31 and a two-hundred day simple moving average of $30.66. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $61.44.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The firm’s revenue was down 7.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.29 earnings per share. Analysts forecast that Omnicell, Inc. will post 0.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on OMCL shares. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and raised their price objective for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. Benchmark reiterated a “buy” rating and issued a $38.00 price target on shares of Omnicell in a research report on Monday, July 15th. JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th. Finally, Wells Fargo & Company raised their price target on Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $37.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.